BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 5.3513

Change

+0.04 (+0.75)%

Market Cap

N/A

Volume

1.21K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.14 (+0.12%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.12 (+0.64%)

USD 557.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.01 (+0.09%)

USD 496.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.45 (-0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.60 (+1.80%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.21 (+0.69%)

USD 209.75B
0QZ3:LSE Qualcomm Inc.

+1.37 (+0.83%)

USD 202.26B
0R24:LSE Intel Corp.

+0.42 (+2.15%)

USD 196.14B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.99% 57% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.99% 55% F 57% F
Trailing 12 Months  
Capital Gain 13.80% 60% D- 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.80% 58% F 60% D-
Trailing 5 Years  
Capital Gain -98.58% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.58% 1% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -15.92% 3% F 8% B-
Dividend Return -15.92% 2% F 8% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.86% 16% F 23% F
Risk Adjusted Return -40.96% 11% F 19% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.